Find new ideas and classic advice on strategy, innovation and leadership, for global leaders from the world's best business ...

The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.

Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks.

A conversation with the cofounder of Intuit on managing both big-picture strategy and the specifics of execution. Senior executives are often told to focus on big-picture strategy while delegating the ...